ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium -

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct_rx - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - 1.1 treatment of gastroesophageal reflux disease (gerd) healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. 1.2 risk reduction of nsaid-associated gastric ulcer esomeprazole magnesium

जॉर्डन - अंग्रेज़ी - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الدولية للدواء - pharma international company - esomeprazole (magnesium trihydrate)40 mg - (magnesium trihydrate)40 mg

जॉर्डन - अंग्रेज़ी - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الدولية للدواء - pharma international company - esomeprazole (magnesium trihydrate)40 mg - (magnesium trihydrate)40 mg

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

bryant ranch prepack - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 40 mg

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate -

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

reliable 1 laboratories llc - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - drug facts active ingredient (in each capsule) esomeprazole 20 mg (each delayed-release capsule corresponds to 22.250 mg esomeprazole magnesium trihydrate) purpose acid reducer uses - treats frequent heartburn (occurs 2 or more days a week) - not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect warnings allergy alert: - do not use if you are allergic to esomeprazole. - esomeprazole may cause severe skin reactions. symptoms may include: - skin reddening - blisters - rash if an allergic reaction occurs, stop use and seek medical help right away. do not use if you have - trouble or pain swallowing food, vomiting with blood, or bloody or black stools - heartburn with lightheadedness, sweating or dizziness - chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness - frequent chest pain these may be signs of a serious condition. see your doctor. ask a doctor before use if you have - had heartburn over 3 m

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

direct rx - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 40 mg - 1.1 treatment of gastroesophageal reflux disease (gerd) healing of erosive esophagitis nexium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of nexium may be considered. in infants 1 month to less than 1 year, nexium is indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated gerd. maintenance of healing of erosive esophagitis nexium is indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease nexium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. 1.2 risk reduction of nsaid-associated gastric ulcer nexium is indicated for the reduction in the occurrence of gastr